Première publication du groupe Mobilux (BUT/Conforama)Rexel : amende de 124 m EUR de la part de l’Autorité de la concurrence (prix dérogés)Kering : S&P a dégradé le rating à BBB+/stableSynlab : Elliott va devenir actionnaire d’Ephios, ouvrant la voie au rachat des minoritaires>...
Synlab: Elliott will become shareholder of Ephios, paving the way for a squeeze-out of minority holdersRexel: France’s competition authority fines Rexel € 124m (special price agreement mechanism)Kering: S&P downgrades rating to BBB+/stableFirst publication of the Mobilux Group (BUT/Conforama)>...
EQS-News: SYNLAB AG / Key word(s): Miscellaneous/Squeeze Out Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow 30.10.2024 / 07:32 CET/CEST The issuer is solely responsible for the content of this announcement. Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreemen...
EQS-News: SYNLAB AG / Schlagwort(e): Sonstiges/Squeeze-Out Cinven erwirbt Elliotts Anteil an SYNLAB AG, Squeeze-Out wird folgen 30.10.2024 / 07:32 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Cinven erwirbt Elliotts Anteil an SYNLAB AG, Squeeze-Out wird folgen Elliott bleibt indirekter Minderheitsaktionär von SYNLAB Der Vorstand der SYNLAB AG („SYNLAB“) wurde darüber informiert, dass die internationale Private-Equity-Gesellschaft Cinven eine Vereinbarung mit Fonds getroffen hat, die von Elliott Advisors (UK) Limited („Elliott“...
The medical lab sector is a resilient one (positive volume dynamics, barriers to entry, low capex) that could allow for higher leverage levels. But the medical lab groups are currently facing headwinds such as price pressure in the routine lab business in France, higher interest rates, lower activity levels in the Research business for Cerba and cyberattacks that affected Synlab’s Italian and UK units. In this sector study we review these developments and the efficiency initiativ...
The medical lab sector is a resilient one (positive volume dynamics, barriers to entry, low capex) that could allow for higher leverage levels. But the medical lab groups are currently facing headwinds such as price pressure in the routine lab business in France, higher interest rates, lower activity levels in the Research business for Cerba and cyberattacks that affected Synlab’s Italian and UK units. In this sector study we review these developments and the efficiency initiativ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.